CJC-1295 (No DAC) + Ipamorelin
A combined product of two unapproved growth-hormone secretagogues; the pairing itself has never been tested in a controlled human trial.
What it is
This is the famous growth-hormone stack sold as a single combined product: a short-acting GHRH analog (CJC-1295 without DAC, essentially Mod GRF 1-29) plus the selective secretagogue ipamorelin.
The pairing logic is real pharmacology — two different receptors converging on GH release — and the outcome evidence is nonexistent: no controlled human trial has ever measured what this stack does to muscle, fat, recovery or sleep. Both components also share a shifting FDA compounding status since 2023.
What researchers have actually studied it for
GH release via two complementary receptors in component-level pharmacology; the combination's marketed outcomes have never been tested in trials.
How it works
CJC-1295 (no DAC) delivers a brief GHRH signal; ipamorelin pulses the ghrelin receptor. Hit both at once and the pituitary's GH release is amplified beyond either alone — a genuine synergy at the hormone-release level, marketed as if it were a synergy at the results level.
Where it came from
The no-DAC/ipamorelin pairing became the compounding world's flagship 'GH optimization' protocol in the 2010s — chosen over stronger secretagogues precisely for its short, pulse-mimicking profile. The combined vial is the retail evolution of that clinic protocol.
What the research record actually contains
- Component pharmacology: each raises GH in early human studies.
- The combination: no controlled trials on any clinical outcome, ever.
- Both components cycled on and off FDA's restricted compounding list (2023–2024) and remain under review.
What's known about risks
Short-term studies of each component reported tolerability; the stack's chronic use in healthy adults has never been safety-characterized. Sustained GH/IGF-1 elevation carries the same theoretical metabolic and proliferative questions as the rest of this category.
Where it stands legally
Unapproved as components and as a combination; compounding eligibility is a live, pharmacy-by-pharmacy question. Prohibited in tested sport.
Worth asking a licensed provider
- 1.What measurable outcome are we pursuing, and what human data connects this stack to it?
- 2.What is today's compounding status for both components at your pharmacy?
- 3.What monitoring — IGF-1, glucose — and what stop rules will we use?